এস্তোনিয়া - এস্তোনীয় - Ravimiamet

umedica netherlands b.v. - atorvastatiin - õhukese polümeerikattega tablett - 20mg 28tk; 20mg 84tk; 20mg 200tk; 20mg 56tk; 20mg 98tk; 20mg 500tk; 20mg 30tk; 20mg 60tk; 20mg 100tk; 20mg 10tk; 20mg 50tk; 20mg 14tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioödeem, pärilik - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

alfasigma s.p.a. - metüültioniiniumkloriid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioödeem, pärilik - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioödeem, pärilik - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofiilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

viiv healthcare bv - abacavir, lamivudine - hiv-nakkused - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - kivexa on näidustatud retroviiruste vastase kombineeritud ravi käigus inimese immuunpuudulikkuse viiruse (hiv) nakkuse raviks täiskasvanutel, noorukitel ja vähemalt 25 kg kaaluvatel lastel. enne algatamist ravi abacavir, sõelumine veo eest hla-b*5701 alleeli tuleks teha kõik hiv-nakatunud patsiendil sõltumata rassilisest päritolust. abacavir ei tohi kasutada patsientidel, teadaolevalt kannavad hla-b*5701 alleeli.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

cipla (eu) limited - olansapiin - schizophrenia; bipolar disorder - psühhoeptikumid - adultsolanzapine on näidustatud skisofreenia ravi. olansapiin on efektiivne, säilitades kliinilist paranemist ajal jätkamine ravi patsientidel, kes on näidanud, esialgne ravi vastuseks. olansapiin on näidustatud ravi mõõduka kuni raske maniakaalse episoodi. patsientidel, kelle maniakaalne episood on vastanud, et olansapiin-ravi, olansapiin on näidustatud kordumise ennetamiseks patsientidel, kellel on bipolaarne häire.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

leo pharma a/s - takroliimus - dermatiit, atoopiline - muud dermatoloogilised preparaadid - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. esinevad neli või enam korda aastas), kes on olnud esialgse vastuse maksimaalselt kuue nädala jooksul ravi kaks korda päevas takroliimus salvi (kahjustused eemaldatud, peaaegu kustutatud või kergelt kahjustatud).